title: Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation.
abstract: Despite advances in detection and therapy, epithelial ovarian cancer (EOC) still represents the most lethal gynecologic malignancy in women worldwide. The high mortality of EOC is mainly due to late-stage diagnosis for more than 70% of patients. There is an urgent need to search for specific and sensitive biomarkers for early diagnosis of EOC. Recently, the cumulative data indicated an essential role for microRNA (miRNA), a class of small non-coding RNAs targeting multiple mRNAs and triggering translation repression and/or RNA degradation, in ovarian caner carcinogenesis and progression. Here, we reviewed the published miRNA expression profiling studies that compared the miRNA expression profiles between EOC tissues or cell lines and normal ovarian tissues or benign ovarian tumor or human primary cultured ovarian surface epithelial cells. A miRNA ranking system that takes the number of comparisons in agreement and direction of differential expression into the consideration was devised and used. Finally, five promising differentially miRNAs (miR-200a, miR-100, miR-141, miR-200b, and miR-200c) were reported with the consistent direction in four or more studies. MiR-200a, miR-200b, miR-200c, and miR-141, all of them belong to miR-200 family, were reported with consistently up-regulated in at least 4 studies, whereas miR-100 was reported with down-regulated in 4 studies. Furthermore, we validated these miRNAs in a clinical setting using qRT-PCR and their dysregulations in EOC tissues confirmed the findings. Conclusively, the five most consistently expressed miRNAs might provide some clues of the potential biomarkers in EOC. Further mechanistic and precise validation studies are needed for their clinical significances and roles in the progression of EOC.
authors: Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin, 300060, China.|Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.|National Clinical Research Centre of Cancer, Tianjin, China.
authors: Ying
authors: Y
authors: Chen
authors: Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin, 300060, China.|Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.|National Clinical Research Centre of Cancer, Tianjin, China.
authors: Lei
authors: L
authors: Zhang
authors: Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin, 300060, China.|Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.|National Clinical Research Centre of Cancer, Tianjin, China.
authors: Quan
authors: Q
authors: Hao
references: Mol Endocrinol. 2010 Feb;24(2):447-63
references: 20081105
references: Cancer Res. 2008 Jan 15;68(2):425-33
references: 18199536
references: Clin Cancer Res. 2008 May 1;14(9):2690-5
references: 18451233
references: Gynecol Oncol. 2009 Jan;112(1):55-9
references: 18954897
references: J Natl Cancer Inst. 2009 Jun 16;101(12):840-1
references: 19509361
references: Cancer Res. 2007 Sep 15;67(18):8699-707
references: 17875710
references: Genes Chromosomes Cancer. 2007 Jan;46(1):1-9
references: 17044060
references: Med Oncol. 2013 Mar;30(1):411
references: 23292834
references: Histopathology. 2010 Nov;57(5):734-43
references: 21083603
references: Int J Cancer. 2012 May 1;130(9):2077-87
references: 21671476
references: J Clin Oncol. 2006 Nov 1;24(31):5043-51
references: 17075124
references: Proc Natl Acad Sci U S A. 2008 May 13;105(19):7004-9
references: 18458333
references: Gynecol Oncol. 2013 Jun;129(3):467-71
references: 23500084
references: PLoS One. 2009;4(4):e5311
references: 19390579
references: J Exp Clin Cancer Res. 2012 Jun 06;31:54
references: 22672859
references: Gastroenterology. 2006 Jun;130(7):2113-29
references: 16762633
references: Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):543-52
references: 18349271
references: Int J Cancer. 2008 Mar 1;122(5):963-8
references: 18098137
references: Oncol Rep. 2012 Apr;27(4):1238-44
references: 22246341
references: Clin Cancer Res. 2009 Sep 1;15(17):5404-13
references: 19690197
references: N Engl J Med. 2008 Dec 18;359(25):2720-2
references: 19092157
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Lancet Oncol. 2011 Mar;12(3):273-85
references: 21345725
references: J Natl Compr Canc Netw. 2008 Sep;6(8):795-802
references: 18926090
references: PLoS One. 2008 Jun 18;3(6):e2436
references: 18560586
references: Oncogene. 2012 Feb 9;31(6):764-75
references: 21725366